Fate Therapeutics

This early-phase study tests a new cancer treatment called FT825 (also known as ONO-8250) in people with advanced solid tumors that have HER2 or other markers. The therapy uses pre-made immune cells (CAR T-cells) that are designed to attack cancer, and may be combined with antibo…

This early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting faulty B-cells. About 244 participan…

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…